1. Home
  2. YQ vs LGVN Comparison

YQ vs LGVN Comparison

Compare YQ & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YQ

17 Education & Technology Group Inc.

HOLD

Current Price

$2.30

Market Cap

22.2M

Sector

Real Estate

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.83

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YQ
LGVN
Founded
2012
2014
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2M
25.9M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
YQ
LGVN
Price
$2.30
$0.83
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
6.5K
465.2K
Earning Date
06-09-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.68
$0.48
52 Week High
$6.45
$1.23

Technical Indicators

Market Signals
Indicator
YQ
LGVN
Relative Strength Index (RSI) 59.25 62.15
Support Level $1.84 $0.62
Resistance Level $2.63 $0.87
Average True Range (ATR) 0.23 0.07
MACD 0.03 0.01
Stochastic Oscillator 81.11 73.23

Price Performance

Historical Comparison
YQ
LGVN

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: